The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tobonone     6-[3-[(3,4- dimethoxyphenyl)methylamino]- 2...

Synonyms: Toborinone, torborinone, CHEMBL116315, SureCN563955, CCRIS 7932, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of torborinone


High impact information on torborinone

  • Acute effects of toborinone on vascular capacitance and conductance in experimental heart failure [5].
  • Data were collected at baseline, after induction of heart failure (microsphere embolization into the left coronary artery), and then after toborinone boluses of 0.1, 0.2, 0.4, and 0.8 mg/kg [5].
  • CONCLUSIONS: OPC-18790 has potent venous and arterial vasodilator effects and moderate inotropic and lusitropic effects without a change in heart rate [1].
  • We studied the contribution and relative dose sensitivities of the inotropic, lusitropic, and vascular effects of OPC-18790 in patients with dilated cardiomyopathy [1].
  • CONCLUSION: These observed differences in energy metabolism between OPC-18790 and amrinone at the high dose may be due to the ability of OPC-18790 to increase CBF in the ischaemic region and which may attributed to its differing effect on overall haemodynamics [6].

Biological context of torborinone


Anatomical context of torborinone


Associations of torborinone with other chemical compounds


Gene context of torborinone

  • No significant differences were observed in toborinone pharmacokinetics between poor and extensive metabolizers via CYP2D6 [16].
  • The ratio of external work to the pressure-volume area (EW/PVA) was similarly increased by both drugs, resulting in an improvement in mechanical efficiency (EW/MVo2) with OPC-18790 (p < 0.05) and in a deterioration with dobutamine (p < 0.05) [10].
  • Toborinone ((+/-)-6-[3-(3,4-dimethoxybenzylamino)-2-hydroxypropoxy]-2(1H)-qui nolinone, CAS 128667-95-8, OPC-18790), a novel cardiotonic agent with an inhibitory action on phosphodiesterase, is known to have a potent positive inotropic action with no positive chronotropic effect [18].

Analytical, diagnostic and therapeutic context of torborinone


  1. Acute cardiovascular effects of OPC-18790 in patients with congestive heart failure. Time- and dose-dependence analysis based on pressure-volume relations. Feldman, M.D., Pak, P.H., Wu, C.C., Haber, H.L., Heesch, C.M., Bergin, J.D., Powers, E.R., Cowart, T.D., Johnson, W., Feldman, A.M., Kass, D.A. Circulation (1996) [Pubmed]
  2. Differential effects of OPC-18790, amrinone and dobutamine on cardiac function and energy metabolism in the guinea-pig isolated ischaemic heart. Itoh, S., Mori, T., Tominaga, M., Ishikawa, M., Koga, K., Yabuuchi, Y. Br. J. Pharmacol. (1995) [Pubmed]
  3. Effects of OPC-18790, a new positive inotropic agent, on canine ventricular arrhythmias. Wu, Z., Awaji, T., Abe, H., Motomura, S., Hashimoto, K. Jpn. J. Pharmacol. (1993) [Pubmed]
  4. Cardiovascular effects of the combination of OPC-18790 and dopamine in halothane-anesthetized dogs. Itoh, S., Mori, T., Yoshida, K., Fujiki, H., Tominaga, M., Yabuuchi, Y. Jpn. J. Pharmacol. (1995) [Pubmed]
  5. Acute effects of toborinone on vascular capacitance and conductance in experimental heart failure. Semeniuk, L.M., Belenkie, I., Tyberg, J.V. Circulation (1998) [Pubmed]
  6. Effects of OPC-18790, a new positive inotropic agent, on energetics in the ischaemic canine heart: a 31P-MRS study. Ishikawa, M., Mori, T., Itoh, S., Fujiki, H., Koga, K., Tominaga, M., Yabuuchi, Y. Cardiovasc. Res. (1995) [Pubmed]
  7. Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: comparison with quinidine and dofetilide. Yang, T., Snyders, D.J., Roden, D.M. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  8. Pharmacokinetics and pharmacodynamics of intravenous OPC-18790 in humans: a novel nonglycosidic inotropic agent. Ohnishi, A., Toyoki, T., Ohno, T., Takeshige, Y., Fujita, T., Kodama, K., Mishima, M., Hirayama, A., Kitani, M., Miyamoto, G. Journal of clinical pharmacology. (1994) [Pubmed]
  9. OPC-18790, a novel positive inotropic agent, has both arterial and venous vascular dilating actions in the dog. Fujiki, H., Mori, T., Yoshida, K., Imaizumi, T., Tominaga, M. Eur. J. Pharmacol. (1996) [Pubmed]
  10. A novel inotropic vasodilator, OPC-18790, reduces myocardial oxygen consumption and improves mechanical efficiency with congestive heart failure. Kanda, H., Yokota, M., Ishihara, H., Nagata, K., Kato, R., Sobue, T. Am. Heart J. (1996) [Pubmed]
  11. Biotransformation of the novel inotropic agent toborinone (OPC-18790) in rats and dogs. Evidence for the formation of novel glutathione and two cysteine conjugates. Kitani, M., Miyamoto, G., Nagasawa, M., Yamada, T., Matsubara, J., Uchida, M., Odomi, M. Drug Metab. Dispos. (1997) [Pubmed]
  12. Effects of toborinone (OPC-18790), a new positive inotropic agent, on action potential in guinea pig sinoatrial node: compared with milrinone and E-4031. Orito, K., Takase, H., Fujiki, H., Mori, T. Jpn. J. Pharmacol. (1996) [Pubmed]
  13. Vascular relaxant effects of toborinone on the isolated canine internal mammary artery. Izumoto, H., Fujiki, H., Kawazoe, K. Surgery today. (2001) [Pubmed]
  14. Toborinone and olprinone, phosphodiesterase III inhibitors, inhibit human platelet aggregation due to the inhibition of both calcium release from intracellular stores and calcium entry. Kageyama, K., Mizobe, T., Nozuchi, S., Hiramatsu, N., Nakajima, Y., Aoki, H. Journal of anesthesia. (2004) [Pubmed]
  15. Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action. Hosokawa, T., Mori, T., Fujiki, H., Kinoshita, S., Takemoto, K., Imaizumi, T., Noda, T., Ohura, M., Tominaga, M., Yabuuchi, Y. Heart and vessels. (1992) [Pubmed]
  16. The effects of concomitant administration of theophylline and toborinone on the pharmacokinetics of both compounds in poor and extensive metabolizers via CYP2D6. Tammara, B., Trang, J.M., Miyamoto, G., Kitani, M., Brisson, J., Bramer, S.L. Journal of clinical pharmacology. (2002) [Pubmed]
  17. Comparative study of toborinone (OPC-18790) and milrinone on energy metabolism in microembolized guinea pig hearts. Ishikawa, M., Koga, K., Fujiki, H., Mori, T., Yabuuchi, Y. Life Sci. (1997) [Pubmed]
  18. Study on the effectiveness of toborinone (OPC-18790) in the treatment of heart failure in patients following cardiac surgery. Hirata, T., Akamatsu, T., Horinokuchi, N., Uchida, O., Kuro, M. Arzneimittel-Forschung. (1999) [Pubmed]
WikiGenes - Universities